Carisoprodol Tablet
NDC 45865-233
Product Information
Carisoprodol is a ANDA-approved product labeled by Medsource Pharmaceuticals. Carisoprodol is used short-term to treat muscle pain and discomfort. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 45865-233 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
111;O
Code Structure Chart
Product Details
What is NDC 45865-233?
What are the uses of this product?
What are Active Ingredients of this product?
- CARISOPRODOL 350 mg/1 - A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CARISOPRODOL (UNII: 21925K482H)
- CARISOPRODOL (UNII: 21925K482H) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSE 2910 (50 MPA.S) (UNII: 1IVH67816N)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197446 - carisoprodol 350 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.